The coronavirus (2019-nCoV) has impacted negatively on the demand of the company’s products globally and due to that Biohit Group’s Net Sales outlook for 2020 has changed.
Archive
Does an undiagnosed atrophic gastritis (acid-free stomach) increase the risk of coronavirus infection, its complications and mortality particularly among elderly people?
Biohit Oyj’s Annual Report is published
Coronavirus Information
Dear Partner,
At this time of global struggle against the coronavirus, Biohit Oyj strives to ensure that our employee´s and partners remain healthy. We have already taken several actions in accordance with guidelines of the Finnish government authorities, incl. allowing office workers to work solely from home.
At the time of writing, there have been no disruptions to kit production. Our factory remains open and we are serving our customers as best as we can. There are certain challenges related to air freight (e.g. airlines have cancelled many flights) and this can manifest in higher freight charges or longer transport duration.
Please contact our Customer Services (cs@biohit.fi) for the latest information regarding the handling of your order.
Additional information
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohit.fi
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit’s Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
Population-based screening by Biohit GastroPanel[®] biomarkers practically eliminates the risk of gastric cancer during a long-term follow-up
Biohit Group Financial Statement Release 2019
Biohit Oyj Financial Statement Release – read more.
Biohit Oyj Financial Calendar, Financial Reporting and Annual General Meeting in 2020
Biohit Oyj Financial Calendar, Biohit Oyj’s Financial Reporting and Annual General Meeting in 2020.
TREATMENT RECOMMENDATION IN RUSSIA: GastroPanel®-biomarkers should be used for detection of gastrointestinal diseases
The Ministry of Health of the Russian Federation’s recommendation for early detection of gastrointestinal diseases is published in the Journal of Gastroenterology, Hepatology, Coloproctology.
BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2019
Biohit Oyj Half Year Financial Report 14 August 2019 at 9:30 am local time (EET)
Two clinical trials with Acetium® capsule for prevention of migraine-type headache have been concluded
In 2014, Biohit Oyj initiated two clinical trials for prevention of migraine-type headache attacks, testing the efficacy of Acetium® capsule. Because of a slow patient enrollment, the trial was subsequently extended to two additional clinical centers abroad. Read more